Pharmaceuticals

Industry Forecast: Cephalosporin Market to Generate $2.64 Billion Revenue by 2029

September 1, 2025 by Marketing Posting

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#What Is the Outlook for the Cephalosporin Market Heading Into 2029?#_x000D_

In recent years, the CD-19 antibody market has seen robust growth. It is projected to expand from a market value of $1.75 billion in 2024 to $1.89 billion in 2025, boasting a compound annual growth rate (CAGR) of 8.3%. This significant growth during the historical period can be credited to factors like the rising occurrence of B-cell malignancies, the advent of immunotherapy, an increase in investments for oncology research, the introduction of CAR-T cell therapies, increased healthcare awareness, and the growth of personalized medicine._x000D_

_x000D_

Anticipated robust growth is on the cards for the CD-19 antibody market, which is projected to balloon to “$2.64 billion in 2029 at a compounding annual growth rate (CAGR) of 8.6%. This growth spike during the predicted timeframe can be contributed to factors such as the escalating need for targeted therapies for cancer, widespread acceptance of intelligent cell treatments, increasing instances of hematologic malignancies, healthcare access widening in emerging markets, and enhancements in immunotherapies and biomanufacturing technologies. Important emerging trends for this foreseeable period include advancements in antibody-drug conjugates, cultivation of bispecific antibodies, incorporation of AI in the design of antibodies, refinements in platforms dealing with cell-cell therapy, the shift towards single-use bioreactors, the advent of nanobody-based therapeutic means, and the automation of biologics production._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=21130&type=smp_x000D_

_x000D_

#Which Factors Are Pushing The Cephalosporin Market Forward?#_x000D_

An expected surge in infectious diseases incidents is forecasted to substantially boost the cephalosporin market’s expansion. Pathogenic microorganisms, such as bacteria, viruses, fungi, and parasites, cause infectious diseases by invading and multiplying, which can spread from person to person, causing diseases like tuberculosis, malaria, and flu. The rise in infectious diseases results in an increased demand for cephalosporin antibiotics, regularly employed to treat bacterial pathogen-induced infectious ailments due to their significant role in controlling and battling bacterial infections. In March 2023, for example, the US-based national public health body, the Centers for Disease Control and Prevention, reported 8,300 tuberculosis (TB) cases in the United States for the year 2022, marking an increase from 7,874 cases in 2021. Consequently, the escalating prevalence of infectious diseases is anticipated to fuel the growth of the cephalosporin market._x000D_

_x000D_

The cd-19 antibody market covered in this report is segmented – _x000D_

_x000D_

1) By Disease Type: B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Other Disease Types_x000D_

2) By Type: Polyclonal, Monoclonal_x000D_

3) By Route Of Administration: Intravenous, Subcutaneous_x000D_

4) By Application: Enzyme Linked Immunosorbent Assay, Flow Cytometry, Immunohistochemistry Frozen, Immunohistochemistry Paraffin, Other Applications_x000D_

_x000D_

Subsegments:_x000D_

1) By B-Cell Non-Hodgkin Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma _x000D_

2) By Chronic Lymphocytic Leukemia: Relapsed Or Refractory CLL, Treatment-Naïve CLL _x000D_

3) By Acute Lymphoblastic Leukemia: B-Cell Precursor ALL, Philadelphia Chromosome-Positive ALL _x000D_

4) By Other Disease Types: Hairy Cell Leukemia, Waldenström’s Macroglobulinemia, Marginal Zone Lymphoma_x000D_

_x000D_

#Which Emerging Trends And Strategic Shifts Are Shaping The Cephalosporin Market?#_x000D_

In the CD-19 antibody market, major industry players are concentrating on the development of innovative technology such as genetically engineered autologous T-cell immunotherapy, aimed at improving the effectiveness of cancer treatments, specifically for blood cancers. This advanced therapy involves modifying a patient’s T cells to recognize and eliminate cancer cells, which are then infused back into the patient’s body to fortify the immune response against the disease. In November 2024, Autolus Therapeutics plc, an American biopharmaceutical firm, received approval from the U.S. FDA for AUCATZYL (obecabtagene autoleucel), a treatment intended for adults suffering from B-cell precursor acute lymphoblastic leukemia (ALL) that has relapsed or become resistant to treatment. The therapeutic design is devised to manage T-cell activation and mitigate toxicity, thereby enhancing the life span of the therapeutic cells. Individual doses, split between days 1 and 10, are determined through a bone marrow assessment prior to treatment._x000D_

_x000D_

#Which Organizations Are Driving Progress In The Cephalosporin Industry?#_x000D_

Major companies operating in the CD-19 antibody market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca plc, Novartis AG, Thermo Fisher Scientific Inc., Amgen Inc., Bio-Rad Laboratories Inc., Miltenyi Biotec GmbH, Abcam Plc, Kite Pharma Inc., BioLegend Inc., Xencor Inc., Juno Therapeutics Inc., BD Biosciences, Zenas BioPharma Inc., Cell Signaling Technology Inc., Santa Cruz Biotechnology Inc., Novus Biologicals LLC, Tonbo Biosciences Inc., Bio X Cell Inc. _x000D_

_x000D_

https://www.thebusinessresearchcompany.com/report/cd-19-antibody-global-market-report_x000D_

_x000D_

#Which Region Is Expected To Experience The Highest Growth In The Cephalosporin Industry?#_x000D_

North America was the largest region in the CD-19 antibody market in 2024. The regions covered in the CD-19 antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=21130&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_